LifeVantage (LFVN) AI Stock Analysis

• Market Cap: $88.84M
• Dividend Yield: 2.43%
• Average Volume (3M): 140.32K
• Price to Earnings (P/E): 9.3
• Beta (1Y): -0.24
• Revenue Growth: 14.17%
• EPS Growth: 235.39%
• Country: US
• Employees: 222
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 0.17
• Shares Outstanding: 12,691,009
• 10 Day Avg. Volume: 142,706
• 30 Day Avg. Volume: 140,324
• PEG Ratio: 0.07
• Price to Book (P/B): 4.63
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 15.25
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $9.50 ▲(11.24% Upside)

LifeVantage's overall stock score reflects a mix of strong financial performance and attractive valuation, offset by bearish technical indicators. The strategic acquisition of LoveBiome and a solid cash position provide a positive outlook, but the decline in free cash flow and bearish market momentum present challenges.

LifeVantage Business Overview & Revenue Model

Company Description

LifeVantage Corporation (LFVN) is a biotechnology company that focuses on developing and marketing dietary supplements and wellness products. The company operates primarily in the health and wellness sector, with a strong emphasis on nutritional supplements that utilize patented technologies to promote cellular health and longevity. Its core product lines include Protandim, a supplement designed to reduce oxidative stress, and other products that support overall health and wellness, targeting both individual consumers and independent distributors.

How the Company Makes Money

LifeVantage generates revenue primarily through the sale of its nutritional supplements and wellness products. The company employs a direct-selling business model, where products are sold through a network of independent distributors who earn commissions on their sales and the sales of their recruited team members. This multi-level marketing structure not only drives sales but also incentivizes distributors to expand their network. Significant revenue streams include product sales to consumers, distributor commissions, and bonuses, which are tied to sales volume and recruitment. Partnerships with health and wellness professionals and affiliations with wellness-related organizations also bolster the company's brand presence and sales efforts, contributing to its overall earnings.

LifeVantage Financial Statement Overview

Summary

LifeVantage demonstrates solid financial performance with strong revenue growth and profitability margins. The balance sheet reflects a stable leverage position and improved return on equity. However, the significant decline in free cash flow growth poses a risk that needs to be addressed.

Income Statement

LifeVantage shows a consistent revenue growth trend with a recent increase of 2.78% in 2025, recovering from previous declines. The gross profit margin remains strong at over 80%, indicating efficient cost management. However, the net profit margin is relatively low at 4.29%, suggesting room for improvement in profitability. The EBIT and EBITDA margins have improved, reflecting better operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has decreased to 0.34, indicating a healthier leverage position compared to previous years. Return on equity has improved significantly to 28.30%, showcasing effective use of equity to generate profits. However, the equity ratio is not explicitly provided, but the overall balance sheet indicates a stable financial position with manageable debt levels.

Cash Flow

Free cash flow has decreased significantly, with a growth rate of -81.8%, which is a concern. However, the operating cash flow to net income ratio is 0.44, indicating that the company generates sufficient cash from operations relative to its net income. The free cash flow to net income ratio is strong at 1.0, suggesting that the company is able to convert its earnings into cash effectively.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	228.53M	228.53M	200.16M	213.40M	206.36M	220.18M
Gross Profit	183.67M	183.67M	158.72M	170.01M	168.26M	181.99M
EBITDA	15.36M	15.36M	7.93M	4.26M	9.75M	23.07M
Net Income	9.80M	9.80M	2.94M	2.54M	3.12M	12.89M
Balance Sheet
Total Assets	71.96M	71.96M	60.30M	66.12M	70.71M	78.73M
Cash, Cash Equivalents and Short-Term Investments	20.20M	20.20M	16.89M	21.61M	20.19M	23.17M
Total Debt	11.68M	11.68M	13.61M	13.09M	15.76M	18.18M
Total Liabilities	37.32M	37.32M	34.31M	31.47M	39.19M	41.92M
Stockholders Equity	34.64M	34.64M	25.99M	34.65M	31.52M	36.81M
Cash Flow
Free Cash Flow	10.51M	10.51M	9.95M	3.76M	6.43M	12.53M
Operating Cash Flow	11.88M	11.88M	12.20M	6.83M	7.96M	16.27M
Investing Cash Flow	-1.37M	-1.37M	-2.25M	-3.06M	-1.53M	-3.73M
Financing Cash Flow	-7.60M	-7.60M	-14.42M	-2.36M	-8.95M	-11.45M

LifeVantage Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Negative. The current price of 8.54 is below the 20-day moving average (MA) of 8.58, below the 50-day MA of 10.12, and below the 200-day MA of 13.52, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 17.05 is Positive, neither overbought nor oversold. The STOCH value of 9.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFVN.

LifeVantage Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	69 Neutral	$242.49M	18.44	9.15%	―	4.33%	-6.33%
LFVN	68 Neutral	$88.84M	9.27	32.34%	2.43%	14.17%	235.39%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
USNA	61 Neutral	$375.49M	23.09	3.20%	―	5.88%	-68.62%
HLF	56 Neutral	$822.78M	2.51	―	―	-2.25%	288.79%
HAIN	43 Neutral	$100.22M	―	-74.88%	―	-10.17%	-609.02%

LifeVantage Corporate Events

LifeVantage Reports Modest Revenue Growth in Q1 2026

LifeVantage Corporation is a health and wellness company specializing in nutrigenomics, offering products that enhance health at the cellular level. In its first fiscal quarter of 2026, LifeVantage reported a modest revenue increase to $47.6 million, up 0.7% from the previous year. The company’s net income per diluted share rose to $0.17 from $0.14, while adjusted earnings per share increased to $0.18 from $0.15. Despite a slight decline in adjusted EBITDA to $3.9 million, LifeVantage remains optimistic about its strategic acquisition of LoveBiome, which is expected to drive future growth. The company continues to focus on expanding its wellness ecosystem and anticipates higher revenue in the latter half of the fiscal year, supported by seasonal trends and the integration of LoveBiome’s offerings.

LifeVantage Corp’s Earnings Call: Strategic Growth Amid Challenges

LifeVantage Corp’s recent earnings call conveyed a cautiously optimistic sentiment, highlighting significant growth in revenue and strategic initiatives. The company showcased a positive outlook with its acquisition of LoveBiome and a new partnership with Shopify, although some concerns were raised regarding the softness in U.S. revenue and a decline in operating income. Overall, the sentiment was more positive than negative, with the company focusing on future growth opportunities.

LifeVantage Reports Strong Fiscal 2025 Performance

LifeVantage Corporation, a leader in the health and wellness industry, specializes in products that activate optimal health processes at the cellular level, offering a unique approach to nutrigenomics.